Novel drug-eluting stent with improved radiographic visibility found to be safe and effective

September 24, 2018, Cardiovascular Research Foundation

This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better X-ray visibility was shown to be non-inferior to an ultrathin-strutted bioresorbable polymer-coated sirolimus-eluting stent (Orsiro) that uses a cobalt-chromium strut platform.

Findings of the BIONYX trial were reported today at the 30th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in The Lancet.

"The vast majority of contemporary stents use stent platforms from cobalt-chromium alloy which allows for the creation of fine mesh tubes with satisfactory radial force, but limited X-ray visibility," said Clemens von Birgelen, MD, Ph.D., an Interventional Cardiologist at Thoraxcentrum Twente and Professor of Interventional Cardiology at the University of Twente in Enschede, The Netherlands. "Sub-optimal radiographic visibility can be challenging in obese patients, when treating bifurcated or calcified coronary lesions, or when carefully assessing stent expansion."

The Resolute Onyx stent was developed in response to the demand for stents with better radiographic visibility which may facilitate the recognition of stents that are not yet well expanded or incompletely apposed to the arterial wall. The stent uses a novel thin strut composite wire stent platform, covered with a zotarolimus-eluting durable polymer coating. The metallic stent platform consists of a composite wire made from a dense platinum-iridium core, which makes the struts radiopaque, and an outer layer of cobalt-chromium alloy. The dense core also allows for a somewhat lower strut thickness. A head-to-head comparison with the Orsiro stent was of interest, as the Orsiro has shown excellent efficacy and safety outcomes in multiple randomized clinical trials, including three large-scale trials in all-comers.

Between October 7, 2015, and December 23, 2016, a total of 2,488 all-comer patients were included in the intention-to-treat analysis. Participants were between 30 and 96 years of age, 594 (23.9%) were women, 1,765 (70.9%) presented with an acute coronary syndrome, and 1,275 (51.2%) were treated for an acute myocardial infarction at the time of study enrollment.

At one-year follow-up, the primary endpoint of target vessel failure was met by 55 (4.5%) of 1,243 patients assigned to Resolute Onyx, and by 58 (4.7%) of 1,245 assigned to Orsiro. Non-inferiority of Resolute Onyx versus Orsiro was established with an absolute risk difference of -0.2% (95% CI -1.9-1.4) and an upper limit of the one-sided 95% CI of 1.1% (pnon-inferiority=0.0005, psuperiority=0.77).

The rates of cardiac death, target vessel-related myocardial infarction, and clinically indicated target vessel revascularization were low and similar in both groups. Definite or probable occurred in a single patient (0.1%) in the Resolute Onyx group and nine patients (0.7%) in the Orsiro group (HR 0.11 [95% CI 0.01-0.87], p=0.0112).

"Despite the difference in stent strut materials and thicknesses and the dissimilar durable and bioresorbable polymer coatings of the two study stents, the BIONYX study found no advantage for one stent over the other," added von Birgelen. "Treatment with both was similarly safe and effective with excellent one-year clinical outcomes in a complex all-comer patient population. The observed very low stent thrombosis rate in Resolute Onyx warrants further clinical investigation."

Explore further: Results from the BIO-RESORT trial presented

More information: Clemens von Birgelen et al, Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial, The Lancet (2018). DOI: 10.1016/S0140-6736(18)32001-4

Related Stories

Results from the BIO-RESORT trial presented

October 31, 2016
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in ...

Results from the tranform-oct study reported

November 7, 2016
Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis (NA) found that bioresorbable polymer-based drug-eluting stents (BP-EES) ...

Results from the BIONICS trial reported

October 31, 2016
The large multinational randomized BIONICS study found that a novel ridaforolimus-eluting stent (BioNIR) was non-inferior to a zotarolimus-eluting stent (Resolute) for one-year clinical outcomes in a broad, less selected ...

Biodegradable stent proves non-inferior to drug-eluting stent

May 21, 2013
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Results of DUTCH PEERS (TWENTE II) trial reported

October 31, 2013
Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish ...

Results of the SORT-OUT VI trial presented

October 30, 2013
A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible ...

Recommended for you

Can liver disease be linked to heart failure? Study highlights liver-heart interaction

November 21, 2018
Virginia Commonwealth University researchers have collaborated on a clinical trial that identifies indicators for nonalcoholic fatty liver disease—a typically asymptomatic disease caused by fat buildup in the liver and ...

New China and US studies back use of pulse oximeters for assessing blood pressure

November 21, 2018
Fast and easy blood pressure monitoring could soon be at your fingertips—literally—thanks to new University of British Columbia research that showed BP can be assessed by a fingertip oximeter, a tool not generally used ...

Gut protein mutations shield against spikes in glucose

November 20, 2018
Why is it that, despite consuming the same number of calories, sodium and sugar, some people face little risk of diabetes or obesity while others are at higher risk? A new study by investigators at Brigham and Women's Hospital ...

Proteins cooperate to break up energy structures in oxygen starved heart cells

November 19, 2018
During a heart attack, the supply of oxygen to heart cells is decreased. This reduced oxygen level, called hypoxia, causes the cell's powerhouses, the mitochondria, to fragment, impairing cell function and leading to heart ...

Bullying and violence at work increases the risk of cardiovascular disease

November 19, 2018
People who are bullied at work or experience violence at work are at higher risk of heart and brain blood vessel problems, including heart attacks and stroke, according to the largest prospective study to investigate the ...

Genetic analysis links obesity with diabetes, coronary artery disease

November 16, 2018
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.